Trial Profile

A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Radium 223 chloride (Primary)
Indications Adenocarcinoma; Bone metastases; Prostate cancer
Focus Therapeutic Use
Sponsors Algeta; Bayer

Most Recent Events

07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
19 Feb 2011 Results were presented in combination with results from the BC1-02 study (59651) at the 2011 Genitourinary Cancers Symposium.
24 Sep 2010 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com